Alzheimer’s disease gradually worsens over time, and there’s no cure for it yet. Leqembi (lecanemab) is a new type of medicine that can slow down how quickly Alzheimer’s disease gets worse.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

New dementia diagnoses have significantly decreased since 2015, a study published in BMJ found.But more people are living ...

The study results on Leqembi, which Eisai shares with Biogen, also found that a patient's Alzheimer's disease worsens after they stop treatment. Rates of adverse side effects associated with ...

Leqembi — sold through a partnership between Eisai and Cambridge-based Biogen Inc. — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

Leqembi is a monoclonal antibody that moderately slows the decline in memory and thinking in patients in the earliest stages of Alzheimer's. Only a narrow swath of the nearly 7 million U.S ...